CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Wilson NR, Bover L, Konopleva M, Han L, et al. Leuk Lymphoma 2022;63:19-30.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wilson NR, Bover L, Konopleva M, Han L, et al. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma 2022;63:19-30.
PMID: 34486917